Advertisement

Adverse Effects of Androgen Deprivation in Elderly Men with Prostate Cancer

  • Ahmad Zarzour
  • Jeffrey W Shevach
  • Alicia K Morgans
Geriatric Urology (T Griebling, Section Editor)
  • 6 Downloads
Part of the following topical collections:
  1. Topical Collection on Geriatric Urology

Abstract

Purpose of Review

The purpose of this review is to summarize the key literature of complications and adverse effects experienced by elderly men undergoing androgen deprivation therapy for prostate cancer, as well as evidence-based strategies to manage these complications.

Recent Findings

Current research demonstrates several adverse effects associated with treatment with androgen deprivation therapy, including skeletal complications, possible cardiovascular effects, diabetes and metabolic complications, decreased sexual function and libido, depression, and cognitive decline.

Summary

Despite the well-known side effect profile of androgen deprivation therapy for prostate cancer, little evidence-based guidance for management of these complications exists outside of skeletal health. Prospective studies are needed to determine the effect of androgen deprivation therapy on cardiovascular disease in older adults, and prospective trials are needed to assess diagnostic and therapeutic interventions in this large, vulnerable patient population.

Keywords

Androgen deprivation Hormonal treatment Prostate cancer Complications Geriatric 

Notes

Compliance with Ethical Standards

Conflicts of Interest

Dr. Morgans reports personal fees from Janssen, Genentech, AstraZeneca, Astellas, Bayer, and Sanofi, outside the submitted work.

Dr. Shevach and Dr. Zarzour each declare no conflict of interest.

Human and Animal Rights

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.Google Scholar
  2. 2.
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer. 2002;2(5):389–96.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–60.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378(26):2465–74.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408–18.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Bilezikian JP. Osteoporosis in men. J Clin Endocrinol Metab. 1999;84(10):3431–4.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Orwoll ES. Osteoporosis in men. Endocrinol Metab Clin N Am. 1998;27(2):349–67.CrossRefGoogle Scholar
  9. 9.
    •• Qaseem A, Forciea MA, McLean RM, Denberg TD. Clinical guidelines committee of the american college of p. treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017;166(11):818–39 This is an important paper from the American College of Physicians that summarizes the guidelines of osteoporosis prevention and treatment including men on hormonal treatment. PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol. 1999;161(4):1219–22.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol. 2002;167(6):2361–7 discussion 7.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 2000;163(1):181–6.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer. 1998;83(8):1561–6.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Haentjens P, Magaziner J, Colon-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med. 2010;152(6):380–90.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154–64.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23(31):7897–903.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    NCCN Clinical practice guidelines in oncology: Prostate cancer. Version 3.2018 2018.Google Scholar
  18. 18.
    Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385–97.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Saylor PJ, Kaufman DS, Michaelson MD, Lee RJ, Smith MR. Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol. 2010;183(6):2200–5.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    DiBlasio CJ, Malcolm JB, Derweesh IH, Womack JH, Kincade MC, Mancini JG, et al. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer. BJU Int. 2008;102(1):39–43.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Potosky AL, Knopf K, Clegg LX, Albertsen PC, Stanford JL, Hamilton AS, et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol. 2001;19(17):3750–7.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Bong GW, Clarke HS Jr, Hancock WC, Keane TE. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer. Urology. 2008;71(6):1177–80.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013;368(14):1314–25.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Holzbeierlein JM, McLaughlin MD, Thrasher JB. Complications of androgen deprivation therapy for prostate cancer. Curr Opin Urol. 2004;14(3):177–83.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Loprinzi CL, Michalak JC, Quella SK, O’Fallon JR, Hatfield AK, Nelimark RA, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med. 1994;331(6):347–52.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448–56.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, Cheung AM, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol. 2009;27(21):3452–8.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Keating NL, O’Malley A, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2012;104(19):1518–23.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Crawley D, Garmo H, Rudman S, Stattin P, Haggstrom C, Zethelius B, et al. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer. Int J Cancer. 2016;139(12):2698–704.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology. 2004;63(4):742–5.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer. 2008;112(10):2188–94.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Hamilton EJ, Gianatti E, Strauss BJ, Wentworth J, Lim-Joon D, Bolton D, et al. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol. 2011;74(3):377–83.CrossRefGoogle Scholar
  33. 33.
    Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006;91(4):1305–8.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Keating NL, Liu PH, O’Malley AJ, Freedland SJ, Smith MR. Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol. 2014;65(4):816–24.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Bradley MC, Zhou Y, Freedman AN, Yood MU, Quesenbery CP, Haque R, et al. Risk of diabetes complications among those with diabetes receiving androgen deprivation therapy for localized prostate cancer. Cancer Causes Control. 2018;29(8):785–91.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Kalyani RR, Golden SH, Cefalu WT. Diabetes and aging: unique considerations and goals of care. Diabetes Care. 2017;40(4):440–3.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Nobes JP, Langley SE, Klopper T, Russell-Jones D, Laing RW. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int. 2012;109(10):1495–502.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Zhu W, Xu H, Ma J, Guo J, Xue W, Gu B, et al. An open-label pilot study of metformin as a concomitant therapy on patients with prostate cancer undergoing androgen deprivation treatment. Urol Int. 2017;98(1):79–84.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Kappert K, Bohm M, Schmieder R, Schumacher H, Teo K, Yusuf S, et al. Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET). Circulation. 2012;126(8):934–41.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Savji N, Rockman CB, Skolnick AH, Guo Y, Adelman MA, Riles T, et al. Association between advanced age and vascular disease in different arterial territories: a population database of over 3.6 million subjects. J Am Coll Cardiol. 2013;61(16):1736–43.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    • Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol. 2015;68(3):386–96 In this meta-analysis of 8 retrospective studies, ADT was associated with worse cardiovascular outcomes, particularly in men with history of cardiovascular disease. Although data from other studies were not conclusive, and patients need to be counseled on these potential serious complications. PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110(7):1493–500.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011;306(21):2359–66.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Morgans AK, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, et al. Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapy. J Urol. 2015;193(4):1226–31.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Nead KT, Boldbaatar N, Yang DD, Sinha S, Nguyen PL. Association of androgen deprivation therapy and thromboembolic events: a systematic review and meta-analysis. Urology. 2018;114:155–62.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Ehdaie B, Atoria CL, Gupta A, Feifer A, Lowrance WT, Morris MJ, et al. Androgen deprivation and thromboembolic events in men with prostate cancer. Cancer. 2012;118(13):3397–406.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    •• Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans AK, et al. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer. Circulation. 2016;133(5):537–41 This is a practical paper that establishes a multistep approach to prevent and manage cardiovascular complications of ADT. This approach should be followed by treating physicians to prevent detrimental effects of such complications. PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    •• Gonzalez BD, Jim HS, Booth-Jones M, Small BJ, Sutton SK, Lin HY, et al. Course and predictors of cognitive function in patients with prostate cancer receiving androgen-deprivation therapy: a controlled comparison. J Clin Oncol. 2015;33(18):2021–7 In this prospective study, patients treated with ADT had worsening cognitive function compared with age-matched controls. The risk of cognitive decline with ADT needs to be considered and patients need to be educated on such risk. PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Cherrier MM, Aubin S, Higano CS. Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer. Psychooncology. 2009;18(3):237–47.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Nead KT, Gaskin G, Chester C, Swisher-McClure S, Dudley JT, Leeper NJ, et al. Androgen deprivation therapy and future Alzheimer’s disease risk. J Clin Oncol. 2016;34(6):566–71.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Nead KT, Gaskin G, Chester C, Swisher-McClure S, Leeper NJ, Shah NH. Association between androgen deprivation therapy and risk of dementia. JAMA Oncol. 2017;3(1):49–55.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Baik SH, Kury FSP, McDonald CJ. Risk of Alzheimer’s disease among senior medicare beneficiaries treated with androgen deprivation therapy for prostate cancer. J Clin Oncol. 2017;35(30):3401–9.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Joly F, Alibhai SM, Galica J, Park A, Yi QL, Wagner L, et al. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol. 2006;176(6 Pt 1):2443–7.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    •• Dinh KT, Reznor G, Muralidhar V, Mahal BA, Nezolosky MD, Choueiri TK, et al. Association of androgen deprivation therapy with depression in localized prostate cancer. J Clin Oncol. 2016;34(16):1905–12 This study showed possible correlation between ADT and depression which can cause significant morbidity in the elderly patients with prostate cancer. PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Nead KT, Sinha S, Yang DD, Nguyen PL. Association of androgen deprivation therapy and depression in the treatment of prostate cancer: a systematic review and meta-analysis. Urol Oncol. 2017;35(11):664 e1- e9.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Dinh KT, Yang DD, Nead KT, Reznor G, Trinh QD, Nguyen PL. Association between androgen deprivation therapy and anxiety among 78 000 patients with localized prostate cancer. Int J Urol. 2017;24(10):743–8.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Ahmad Zarzour
    • 1
  • Jeffrey W Shevach
    • 1
  • Alicia K Morgans
    • 1
  1. 1.Robert H. Lurie Comprehensive Cancer CenterNorthwestern UniversityChicagoUSA

Personalised recommendations